CD274 and neoplasm: A phase 2 trial specifically assessing the impact of anti-PD-1 monotherapy in NSCLC patients with brain metastases showed an ORR of 29.7% in the subset of patients whose tumor expressed PD-L1, suggesting some activity in NSCLC brain metastases (94).